Sage Journals: Discover world-class research

Abstract

Background

Renal denervation (RDN) is believed to reduce sympathetic nerve activity and is a potential treatment for resistant hypertension. The present study investigated the effects of RDN on end organ damage (EOD).

Design

The present study was a prospective cohort study (registered as NCT01427049).

Methods

Uncontrolled hypertensive patients underwent a work-up prior to and one year after RDN. Cardiac magnetic resonance (CMR) imaging was used to determine left ventricular (LV)-mass; pulse wave analysis and pulse wave velocity (PWV) were used for evaluation of central blood pressure (BP) and arterial stiffness and 24-hour urine was collected for assessment of urinary albumin excretion. The 24-hour ambulatory BP measurement (ABPM) was used to evaluate the effect of RDN on BP.

Results

Fifty-four patients gave informed consent for study participation. Mean age was 58 ± 10 years, 50% were male. One year after RDN, mean ABPM decreased by 7 ± 18/5 ± 11 mm Hg (p = 0.01/p < 0.01). In the patients followed-up in a standardised fashion ABPM decreased by 5 ± 18/4 ± 12 mm Hg (n = 34; p = 0.11/p = 0.09). Mean body surface area indexed LV-mass decreased by 3.3 ± 11.5 g/m² (corresponding to a 3 ± 11% reduction; p = 0.09). PWV increased by 2.9 (−2.2 to +6.1) m/s (p = 0.04). Augmentation index corrected for 75 beats per min did not change (median increase 3.0 (−7 to +17) mm Hg; p = 0.89). Urinary albumin excretion did not change during follow-up (mean decrease 10 ± 117 mg/24 hour; p = 0.61).

Conclusion

In the current study, we observed a modest effect from renal denervation. Moreover, RDN did not result in a statistical significant effect on end organ damage 12 months after treatment.

Keywords

Renal denervation end organ damage left ventricular hypertrophy arterial stiffness albuminuria

Get full access to this article

View all access options for this article.

References

Yoon SS, Burt V, Louis T, et al. Hypertension among adults in the United States, 2009–2010. NCHS Data Brief 2012; 107: 1–8.

Global Health Observatory G. Raised blood pressure. Situation and Trends 2013. Available at: http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/.

Grassi

Seravalle

Dell'Oro

. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep 2011; 13: 303–308.

Vernooij

van der Graaf

Nathoe

. Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease. J Hypertens 2013; 31: 492–499.

Calhoun

Jones

Textor

. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–e526.

Muiesan

Salvetti

Rizzoni

. Resistant hypertension and target organ damage. Hypertens Res 2013; 36: 485–491.

Grassi

. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23: 1052–1060.

Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622–629.

Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 Month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752–1759.

10.

Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393–1401.

11.

Verloop

Vink

Voskuil

. Eligibility for percutaneous renal denervation: The importance of a systematic screening. J Hypertens 2013; 31: 1662–1668.

12.

Pickering

Hall

Appel

. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697–716.

13.

Jaspers

Freling

van Wijk

. Improving the reproducibility of MR-derived left ventricular volume and function measurements with a semi-automatic threshold-based segmentation algorithm. Int J Cardiovasc Imaging 2013; 29: 617–623.

14.

van Dijk

Smulders

Enneman

. Homocysteine level is associated with aortic stiffness in elderly: Cross-sectional results from the B-PROOF study. J Hypertens 2013; 31: 952–959.

15.

Stevens PE, Levin A and Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825–830.

16.

Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932–934.

17.

Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: What, why, and how? Br Med J 2009; 338: b375.

18.

Staessen

Wang

Thijs

. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305–1315.

19.

Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–81.

20.

Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010; 376: 1903–1909.

21.

Mancia

Fagard

Narkiewicz

. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.

22.

Siddiqi

Prakken

Velthuis

. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010; 25: 3272–3277.

23.

Brandt

Mahfoud

Reda

. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901–909.

24.

Schirmer SH, Sayed MM, Reil JC, et al. Improvements of left-ventricular hypertrophy and diastolic function following renal denervation – effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 2013; 63: 1916–1923.

25.

Armstrong

Gidding

Gjesdal

. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 2012; 5: 837–848.

26.

Brandt

Reda

Mahfoud

. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60: 1956–1965.

27.

Ott

Janka

Schmid

. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol 2013; 8: 1195–1201.

28.

Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–1225.

29.

Monster TB, Janssen WM, de Jong PE, et al. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002; 53: 31–6.

30.

Fogari

Mugellini

Zoppi

. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 2005; 61: 483–490.

31.

Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17: 259–266.

32.

Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319–323.

33.

Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29–34.

34.

Blankestijn PJ, Alings M, Voskuil M, et al. The complexity after simplicity: How to proceed with renal denervation in hypertension? Eur J Prev Cardiol. Epub ahead of print 9 June 2014. DOI: 2047487314538859.

35.

Miller M, Gangireddy S, Dukkipati S, et al. Renal sympathetic denervation using an electroanatomical mapping system. J Am Coll Cardiol 2014; 63: 1697.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.23 MB